|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Parekh A, Graham PL and Nguyen PL: Cancer
control and complications of salvage local therapy after failure of
radiotherapy for prostate cancer: A systematic review. Semin Radiat
Oncol. 23:222–234. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Seruga B and Tannock IF:
Chemotherapy-based treatment for castration-resistant prostate
cancer. J Clin Oncol. 29:3686–3694. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Petrylak DP: Chemotherapy for advanced
hormone refractory prostate cancer. Urology. 54(6A Suppl): S30–S35.
1999. View Article : Google Scholar
|
|
5
|
Dhar S, Kolishetti N, Lippard SJ and
Farokhzad OC: Targeted delivery of a cisplatin prodrug for safer
and more effective prostate cancer therapy in vivo. Proc Natl Acad
Sci USA. 108:pp. 1850–1855. 2011; View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hager S, Ackermann CJ, Joerger M,
Gillessen S and Omlin A: Anti-tumour activity of platinum compounds
in advanced prostate cancer-a systematic literature review. Ann
Oncol. 27:975–984. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Basourakos SP, Li L, Aparicio AM, Corn PG,
Kim J and Thompson TC: Combination platinum-based and DNA damage
response-targeting cancer therapy: Evolution and future directions.
Curr Med Chem. 24:1586–1606. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Galanski M: Recent developments in the
field of anticancer platinum complexes. Recent Pat Anticancer Drug
Discov. 1:285–295. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Armstrong DK, Bundy B, Wenzel L, Huang HQ,
Baergen R, Lele S, Copeland LJ, Walker JL and Burger RA;
Gynecologic Oncology Group, : Intraperitoneal cisplatin and
paclitaxel in ovarian cancer. N Engl J Med. 354:34–43. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Harzstark AL and Ryan CJ: Novel
therapeutic strategies in development for prostate cancer. Expert
Opin Investig Drugs. 17:13–22. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Su NW, Leu YS, Lee JC, Chen YJ, Chen HW,
Liu CJ and Chang YF: Comparison of the efficacy and toxicity of two
dose levels of cisplatin/5-fluorouracil as the chemoradiotherapy
regimen for the treatment of locally advanced squamous cell
carcinoma of the head and neck. Acta Otolaryngol. 131:1333–1340.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Herrmann J, Yang EH, Iliescu CA,
Cilingiroglu M, Charitakis K, Hakeem A, Toutouzas K, Leesar MA,
Grines CL and Marmagkiolis K: Vascular toxicities of cancer
therapies: The old and the new-an evolving avenue. Circulation.
133:1272–1289. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Stefenelli T, Kuzmits R, Ulrich W and
Glogar D: Acute vascular toxicity after combination chemotherapy
with cisplatin, vinblastine, and bleomycin for testicular cancer.
Eur Heart J. 9:552–556. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Varveris H, Delakas D, Anezinis P,
Haldeopoulos D, Mazonakis M, Damilakis J, Metaxaris G, Chondros N,
Mavromanolakis E, Daskalopoulos G, et al: Concurrent platinum and
docetaxel chemotherapy and external radical radiotherapy in
patients with invasive transitional cell bladder carcinoma. A
preliminary report of tolerance and local control. Anticancer Res.
17:4771–4780. 1997.PubMed/NCBI
|
|
15
|
Pu J, Qin SS, Ding JX, Zhang Y, Zhu WG, Yu
CH, Li T, Tao GZ, Ji FZ, Zhou XL, et al: A randomized controlled
study of single-agent cisplatin and radiotherapy versus
docetaxel/cisplatin and radiotherapy in high-risk early-stage
cervical cancer after radical surgery. J Cancer Res Clin Oncol.
139:703–708. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kelland L: The resurgence of
platinum-based cancer chemotherapy. Nat Rev Cancer. 7:573–584.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wei Q, Frazier ML and Levin B: DNA repair:
A double-edged sword. J Natl Cancer Inst. 92:440–441. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wood RD: Nucleotide excision repair in
mammalian cells. J Biol Chem. 272:23465–23468. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Reed E: ERCC1 and clinical resistance to
platinum-based therapy. Clin Cancer Res. 11:6100–6102. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cummings M, Higginbottom K, McGurk CJ,
Wong OG, Köberle B, Oliver RT and Masters JR: XPA versus ERCC1 as
chemosensitising agents to cisplatin and mitomycin C in prostate
cancer cells: Role of ERCC1 in homologous recombination repair.
Biochem Pharmacol. 72:166–175. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Núñez F, Chipchase MD, Clarke AR and
Melton DW: Nucleotide excision repair gene (ERCC1) deficiency
causes G(2) arrest in hepatocytes and a reduction in liver
binucleation: The role of p53 and p21. FASEB J. 14:1073–1082. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Brozovic A and Osmak M: Activation of
mitogen-activated protein kinases by cisplatin and their role in
cisplatin-resistance. Cancer Lett. 251:1–16. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Siddik ZH: Cisplatin: Mode of cytotoxic
action and molecular basis of resistance. Oncogene. 22:7265–7279.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yeh PY, Chuang SE, Yeh KH, Song YC, Ea CK
and Cheng AL: Increase of the resistance of human cervical
carcinoma cells to cisplatin by inhibition of the MEK to ERK
signaling pathway partly via enhancement of anticancer drug-induced
NF kappa B activation. Biochem Pharmacol. 63:1423–1430. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Walczak H, Miller RE, Ariail K, Gliniak B,
Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, et al:
Tumoricidal activity of tumor necrosis factor-related
apoptosis-inducing ligand in vivo. Nat Med. 5:157–163. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sheikh MS, Burns TF, Huang Y, Wu GS,
Amundson S, Brooks KS, Fornace AJ Jr and el-Deiry WS: p53-dependent
and -independent regulation of the death receptor KILLER/DR5 gene
expression in response to genotoxic stress and tumor necrosis
factor alpha. Cancer Res. 58:1593–1598. 1998.PubMed/NCBI
|
|
27
|
Nagane M, Pan G, Weddle JJ, Dixit VM,
Cavenee WK and Huang HJ: Increased death receptor 5 expression by
chemotherapeutic agents in human gliomas causes synergistic
cytotoxicity with tumor necrosis factor-related apoptosis-inducing
ligand in vitro and in vivo. Cancer Res. 60:847–853.
2000.PubMed/NCBI
|
|
28
|
Shankar S, Chen X and Srivastava RK:
Effects of sequential treatments with chemotherapeutic drugs
followed by TRAIL on prostate cancer in vitro and in vivo.
Prostate. 62:165–186. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Baritaki S, Huerta-Yepez S, Sakai T,
Spandidos DA and Bonavida B: Chemotherapeutic drugs sensitize
cancer cells to TRAIL-mediated apoptosis: Up-regulation of DR5 and
inhibition of Yin Yang 1. Mol Cancer Ther. 6:1387–1399. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang XN, Zhang HJ, Ren DM, Ji M, Yu WT and
Lou HX: Lobarialides A-C, antifungal triterpenoids from the lichen
Lobaria kurokawae. Chem Biodivers. 6:746–753. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu YQ, Gao FB, Jiang HM, Niu LL, Bi YL,
Young CY, Yuan HQ and Lou HX: Induction of DNA damage and ATF3 by
retigeric acid B, a novel topoisomerase II inhibitor, promotes
apoptosis in prostate cancer cells. Cancer Lett. 337:66–76. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu YQ, Ji Y, Li XZ, Tian KL, Young CY,
Lou HX and Yuan HQ: Retigeric acid B-induced mitophagy by oxidative
stress attenuates cell death against prostate cancer cells in
vitro. Acta Pharmacol Sin. 34:1183–1191. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu YQ, Hu XY, Lu T, Cheng YN, Young CY,
Yuan HQ and Lou HX: Retigeric acid B exhibits antitumor activity
through suppression of nuclear factor-kappaB signaling in prostate
cancer cells in vitro and in vivo. PLoS One. 7:e380002012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liu Y, Wang M, Wang D, Li X, Wang W, Lou H
and Yuan H: Malformin A1 promotes cell death through induction of
apoptosis, necrosis and autophagy in prostate cancer cells. Cancer
Chemother Pharmacol. 77:63–75. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lecumberri E, Dupertuis YM, Miralbell R
and Pichard C: Green tea polyphenol epigallocatechin-3-gallate
(EGCG) as adjuvant in cancer therapy. Clin Nutr. 32:894–903. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kim MK, James J and Annunziata CM:
Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce
apoptosis in ovarian cancer cells. BMC Cancer. 15:1962015.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zdraveski ZZ, Mello JA, Farinelli CK,
Essigmann JM and Marinus MG: MutS preferentially recognizes
cisplatin-over oxaliplatin-modified DNA. J Biol Chem.
277:1255–1260. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ko H, Jeong MH, Jeon H, Sung GJ, So Y, Kim
I, Son J, Lee SW, Yoon HG and Choi KC: Delphinidin sensitizes
prostate cancer cells to TRAIL-induced apoptosis, by inducing DR5
and causing caspase-mediated HDAC3 cleavage. Oncotarget.
6:9970–9984. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Shin SW and Park JW: Ursolic acid
sensitizes prostate cancer cells to TRAIL-mediated apoptosis.
Biochim Biophys Acta. 1833:723–730. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Park SJ, Park SH, Kim JO, Kim JH, Park SJ,
Hwang JJ, Jin DH, Jeong SY, Lee SJ, Kim JC, et al: Carnitine
sensitizes TRAIL-resistant cancer cells to TRAIL-induced apoptotic
cell death through the up-regulation of Bax. Biochem Biophys Res
Commun. 428:185–190. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Charette N, De Saeger C, Horsmans Y,
Leclercq I and Stärkel P: Salirasib sensitizes hepatocarcinoma
cells to TRAIL-induced apoptosis through DR5 and survivin-dependent
mechanisms. Cell Death Dis. 4:e4712013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yoon MJ, Kang YJ, Kim IY, Kim EH, Lee JA,
Lim JH, Kwon TK and Choi KS: Monensin, a polyether ionophore
antibiotic, overcomes TRAIL resistance in glioma cells via
endoplasmic reticulum stress, DR5 upregulation and c-FLIP
downregulation. Carcinogenesis. 34:1918–1928. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lin T, Ding Z, Li N, Xu J, Luo G, Liu J
and Shen J: 2-Tellurium-bridged β-cyclodextrin, a thioredoxin
reductase inhibitor, sensitizes human breast cancer cells to
TRAIL-induced apoptosis through DR5 induction and NF-κB
suppression. Carcinogenesis. 32:154–167. 2011. View Article : Google Scholar : PubMed/NCBI
|
